Timeliness and actionable intelligence over I-Banks research which remains only geared to institutional investors and legacy processes. News carries with it a promise of transparency, a light that can be shined into previously dark corners.
But they don’t define any relevance to the actual value of a release - mostly due to SEC forward looking parameters. However, this news portal has been expanded to … supplement, measure and price the event and relevance to a company’s ... valuation.
March 16, 2019
Regenerative Medicine Earnings Scorecard - Q4/18 - to date
February 26, 2019
Sage Therapeutics (SAGE) prices 3.33 M share offering at $150.00
January 29, 2019
RegMed Investors’ (RMi) mid-day: bottoms bounce
January 21, 2019
RegMed Investors’ (RMi): worried about 2019, investors better be!
January 15, 2019
Alnylam Pharmaceuticals (ALNY) priced 5 M share offering at $77.50
December 24, 2018
Merry Christmas and Happy Holiday to All
November 23, 2018
Regenerative Medicine Earnings Scorecard - Q3/18 - to date
November 22, 2018
Happy Thanksgiving ... giving thanks and be SAFE!
November 7, 2018
Quarterly (Q3) results special: ATHX, BOLD, BLCM and GBT
November 6, 2018
Quarterly (Q3) results special: IONS, ONCE, QURE and VCEL
9 hours 8 min ago
RegMed Investors’ (RMi) pre-open: gain or pain
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors